INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3

New pyrimidine or pyridine based compounds, having the structure (I), compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be empl...

Full description

Saved in:
Bibliographic Details
Main Authors PFISTER, KEITH, B, SUBRAMANIAN, SHARADHA, WAGMAN, ALLAN, S, RENHOWE, PAUL, A, JOHNSON, KIRK, RING, DAVID, B, HARRISON, STEPHEN, D, GOFF, DANE, SEELY, LYNN, BOYCE, RUSTUM, S, RAMURTHY, SAVITHRY, ZHOU, XIAOHUI, A, NUSS, JOHN, M, BROWN, SEAN, P
Format Patent
LanguageEnglish
French
Published 23.12.1999
Edition6
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:New pyrimidine or pyridine based compounds, having the structure (I), compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder immunodeficiency or cancer. L'invention concerne de nouveaux composés à base de pyrimidine ou de pyridine de la structure (I), des compositions et méthodes d'inhibition de l'activité de glycogène synthase kinase (GSK3) in vitro et de traitement de troubles induits par GSK3 in vivo. Les méthodes, composés et compositions de la présente invention peuvent s'utiliser seuls ou en combinaison avec d'autres agents actifs du point de vue pharmacologique pour le traitement de troubles induits par l'activité de GSK3, tels que le diabète, la maladie d'Alzheimer et d'autres troubles neurodégénératifs, l'obésité, une maladie cardiovasculaire athéroscléreuse, l'hypertension artérielle essentielle, le syndrome des ovaires polkykystiques, le syndrome X, l'ischémie, le traumatisme cérébral, un trouble bipolaire, l'immunodéficience ou le cancer.
Bibliography:Application Number: WO1999US13809